CHM chimeric therapeutics limited

The general small cap bio-tech business model is:1. Licence an...

  1. 14,262 Posts.
    lightbulb Created with Sketch. 4256
    The general small cap bio-tech business model is:

    1. Licence an above average promising asset

    2. IPO based on pre-clinical data

    3. Raise, based on successful updates, at a higher price

    4. Sell / partner after ph1, ph 2 - depending on market interest / data quality


    CHM / IMU / RAD have failed over the past 3 years to raise at higher levels. The opposite was the case and CHM and RAD clearly demonstrated what the final outcome will be if that way is the model. RAD got ( hopefully ) rescued, IMU still alive but CHM can't survive that way.

    IF they can't raise based on data quality then either the quality isn't good enough or seen as not good enough or the business isn't worth to be continued. Selling / partnering CHM 1101 should be done asap. First time we got told that it isn't going to benefit at this stage.

    Sometimes things won't work out as planned but then a decision must be made, even if it's painful. I just hope we won't get "enlightened" about IMU being in a similar situation. But with the same man making the decisions - or even worse, making no / wrong decisions - it is a huge gamble.

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
0.4¢
Change
-0.001(12.5%)
Mkt cap ! $11.37M
Open High Low Value Volume
0.3¢ 0.4¢ 0.3¢ $10.43K 3.475M

Buyers (Bids)

No. Vol. Price($)
75 70427742 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 84897305 25
View Market Depth
Last trade - 10.14am 31/07/2025 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.